Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Emergent BioSolutions Inc (NYSE:EBS)

38.23
Delayed Data
As of 1:34pm ET
 +0.38 / +1.00%
Today’s Change
27.68
Today|||52-Week Range
40.96
-4.45%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.5B

Company Description

Emergent BioSolutions, Inc. is a biopharmaceutical company. It focuses on the research, development and manufacture of novel vaccines and related products for prophylactic and therapeutic use against common diseases and biological weapons of mass destruction. The company operates through two segments: Biodefense and Biosciences. The Biodefense segment focuses on vaccines and antibody therapies for use against the infectious disease anthrax. The Biosciences segment focuses on protein therapies to treat certain types of cancer and vaccines for use against infectious diseases. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.

Contact Information

Emergent BioSolutions, Inc.
400 Professional Drive
Gaithersburg Maryland 20879
P:(240) 631-3200
Investor Relations:
(301) 795-1877

Employees

Shareholders

Other institutional45.38%
Mutual fund holders42.35%
Individual stakeholders23.14%

Top Executives

Daniel J. Abdun-NabiPresident, Chief Executive Officer & Director
Robert G. KramerCFO, Treasurer & Executive VP-Corporate Services
W. James JacksonChief Scientific Officer & Senior Vice President
Adam R. HaveyExecutive VP & President-BioDefense Division
Anatolio B. CruzSecretary, Executive VP & General Counsel